Movement Alert｜WUXI BIO Rises 4.85% in Regular Trading, CXO Sector Broad Rally Lifts Life Sciences Stocks

Market Focus08-04

On August 4, WUXI BIO rose 4.85% in regular trading, trading at 40.08 HKD/share, with turnover of approximately HKD 215 million.

On the news front, the life sciences tools and services sector experienced a broad-based rally, with peer WUXI APPTEC surging 11.91%, PHARMARON up 5.73%, GENSCRIPT BIO up 4.79%, and WUXI XDC up 3.74%, indicating strong sector-wide momentum in the CXO space.

Multiple positive catalysts have converged for the sector. The company's board is scheduled to review interim results on August 25, creating earnings anticipation. Additionally, the company has maintained an active share buyback program, repurchasing over HKD 1.17 billion worth of shares through late June. Its MFG8 drug substance facility recently received FDA Pre-License Inspection approval for a potential blockbuster autoimmune therapy, marking a key milestone for commercial-scale manufacturing capability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172558138?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172558138","market":"hk","top_or_hot":-1,"title":"Movement Alert｜WUXI BIO Rises 4.85% in Regular Trading, CXO Sector Broad Rally Lifts Life Sciences Stocks","media":"Market Focus","content":"<p><p>On August 4, WUXI BIO rose 4.85% in regular trading, trading at 40.08 HKD/share, with turnover of approximately HKD 215 million.</p><p>On the news front, the life sciences tools and services sector experienced a broad-based rally, with peer WUXI APPTEC surging 11.91%, PHARMARON up 5.73%, GENSCRIPT BIO up 4.79%, and WUXI XDC up 3.74%, indicating strong sector-wide momentum in the CXO space.</p><p>Multiple positive catalysts have converged for the sector. The company's board is scheduled to review interim results on August 25, creating earnings anticipation. Additionally, the company has maintained an active share buyback program, repurchasing over HKD 1.17 billion worth of shares through late June. Its MFG8 drug substance facility recently received FDA Pre-License Inspection approval for a potential blockbuster autoimmune therapy, marking a key milestone for commercial-scale manufacturing capability.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI BIO Rises 4.85% in Regular Trading, CXO Sector Broad Rally Lifts Life Sciences Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI BIO Rises 4.85% in Regular Trading, CXO Sector Broad Rally Lifts Life Sciences Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-04 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 4, WUXI BIO rose 4.85% in regular trading, trading at 40.08 HKD/share, with turnover of approximately HKD 215 million.</p><p>On the news front, the life sciences tools and services sector experienced a broad-based rally, with peer WUXI APPTEC surging 11.91%, PHARMARON up 5.73%, GENSCRIPT BIO up 4.79%, and WUXI XDC up 3.74%, indicating strong sector-wide momentum in the CXO space.</p><p>Multiple positive catalysts have converged for the sector. The company's board is scheduled to review interim results on August 25, creating earnings anticipation. Additionally, the company has maintained an active share buyback program, repurchasing over HKD 1.17 billion worth of shares through late June. Its MFG8 drug substance facility recently received FDA Pre-License Inspection approval for a potential blockbuster autoimmune therapy, marking a key milestone for commercial-scale manufacturing capability.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1172558138","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172558138","pubTimestamp":1785807190,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 4, WUXI BIO rose 4.85% in regular trading, trading at 40.08 HKD/share, with turnover of approximately HKD 215 million.On the news front, the life sciences tools and services sector...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"走势提醒|药明生物常规交易上涨4.85%，CXO板块普涨提振生命科学股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On August 4, WUXI BIO rose 4.85% in regular trading, trading at 40.08 HKD/share, with turnover of approximately HKD 215 million.On the news front, the life sciences tools and services sector experienced a broad-based rally, with peer WUXI APPTEC surging 11.91%, PHARMARON up 5.73%, GENSCRIPT BIO up 4.79%, and WUXI XDC up 3.74%, indicating strong sector-wide momentum in the CXO space.Multiple positive catalysts have converged for the sector. The company's board is scheduled to review interim results on August 25, creating earnings anticipation. Additionally, the company has maintained an active share buyback program, repurchasing over HKD 1.17 billion worth of shares through late June. Its MFG8 drug substance facility recently received FDA Pre-License Inspection approval for a potential blockbuster autoimmune therapy, marking a key milestone for commercial-scale manufacturing capability.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172558138","isCrawlerRequest":true}